Subnavigation

• Genomics home
• Health professionals
• Policy makers
• Patients and public
• Ethical, legal and social implications
• Research
• Craniofacial anomalies

Genetic treatment and technologies

Genetic testing and screening

2005

• Genetic Testing For Alzheimer’s Disease And Its Impact On Insurance Purchasing Behavior
  Cathleen D. Zick, Charles J. Mathews, J. Scott Roberts, Robert Cook-Deegan, Robert J. Pokorski and Robert C. Green
  Health Affairs 2005, Vol 24, Issue 2, 483-490
• Pediatricians' attitudes toward expanding newborn screening
  Kruti Acharya, Paul D. Ackerman, and Lainie Friedman Ross,
  PEDIATRICS Vol. 116 No. 4 October 2005, pp. e476-e484
• Practical and Ethical Issues with Genetic Screening
  John E. Wagner
  Hematology pgs 498 - 502, 2005
• Ethical Issues in Genetic Testing
  Dale Halsey Lea RN, MPH , Janet Williams RN, PhD and M. Patricia Donahue RN, PhD
  Journal of Midwifery & Women's Health Volume 50, Issue 3 ,Pages 234-240 May-June 2005

2004

• Keep genome data freely accessible
  The Lancet 25 September 2004, Vol 364, Issue 9440 , Pg 1099-1100
• Gene Therapy Progress and Prospects. Downregulating gene expression: the impact of RNA interference
  N J Caplen
  Gene Therapy 2004 August; Vol 11; No 16; Pg 1241-1248
• Adherence with colorectal cancer screening guidelines: a review
  Sujha Subramanian , Michelle Klosterman , Mayur M. Amonkar, Timothy L. Hunt
  Preventive Medicine 2004 May, Vol 38, Issue 5 , 536-550
• Cervical cancer screening among Latinas recently immigrated to the United States
  Maria Eugenia Fernandez-Esquer, Marylou Cardenas-Turanzas
  Preventive Medicine 2004 May, Vol 38, Issue 5 , 529-535
• Genetic privacy: Resolving the conflict between the donor and the child
  Saionton Basu
  CURRENT SCIENCE , VOL. 86, NO. 10, 25 MAY 2004
• Community-Based screening for cardiovascular disease and diabetes using HbA1c
  Taneisha Grant, BS, Yukmila Soriano, BS, Paul R. Marantz, MD, MPH, Ingrid Nelson, MD, Eric Williams, MD, Diana Ramirez, MD, Jean Burg, MD, Charles Nordin, MD
  American Journal of Preventive Medicine 2004 April, Vol 26, Issue 4 , 271-275

2003

• The Southwest of Scotland Structural Chromosomal Abnormalities Database: an assessment of its contribution to genetic counselling in affected families.
  Joss SK, Longman CA, Kumar AJ, Younger R, Morrison R, Begum F, Colgan J, Tolmie JL.
  Genetic Counseling 2003; 14(2): 187-94.
• Professional and personal attitudes about access and confidentiality in the genetic testing of children: a pilot study.
  Campbell E, Ross LF.
  Genetic Testing 2003; 7(2): 123-30.
• Attitudes and knowledge about presymptomatic genetic testing among individuals at high risk for familial, early-onset Alzheimer's disease.
  Marcheco B, Bertoli AM, Rojas I, Heredero L
  Genetic Testing 2003; 7(1): 45-7
• International genetic testing.
  Cox SM, Faucett WA, Chen B, Dequeker E, Boone DJ, McGovern MM, Lubin IM.
  Genetics in Medicine 2003; 5(3): 176-82.
• Population screening in the age of genomic medicine.
  Khoury MJ, McCabe LL, McCabe ER.
  New England Journal of Medicine 2003; 348(1): 50-8
• Who gets the information about genetic testing for cancer risk? The role of race/ethnicity, immigration status, and primary care clinicians.
  Honda K
  Clinical Genetics 2003; 64(2): 131
• It's only teeth - are there limits to genetic testing?
  Aldred MJ, Crawford PJM, Savarirayan R, and Savulescu J.
  Clinical Genetics 2003; 63(5): 333
• The complicity of segmental duplicity in human genetic disease.
  Lewis MES
  Clinical Genetics 2003; 63(4): 262
• Searching the vast array of genomic disorders.
  Lewis MES
  Clinical Genetics 2003; 63(4): 266-267
• Genetic counseling for prostate cancer risk.
  Nieder AM, Taneja SS, Zeegers MPA, Ostrer H.
  Clinical Genetics 2003; 63(3): 169-176.
• Psychosocial issues in cancer genetics--current status and future directions.
  Bleiker EM, Hahn DE, Aaronson NK.
  Acta Oncologica 2003; 42(4):276-86
• The ethical management of genetic testing.
  Haites NE
  European Journal of Cancer 2003; 39(10): 1339-1340

2002

• Family issues in a psychoeducation group for women with a BRCA mutation.
  Speice J, McDaniel SH, Rowley PT, Loader S.
  Clinical Genetics 2002 62(2): 121-127

2001

• Goals of Genetic Counseling.
  Biesecker BB.
  Clinical Genetics 2001; 60(5): 323
• Multicultural education and genetic counseling.
  Weil J.
  Clinical Genetics 2001; 59(3): 143

---

Gene therapy

2005

• Gene therapy progress and prospects: Novel gene therapy approaches for AIDS
  R Wolkowicz and G P Nolan
  Gene Therapy March 2005, Volume 12, Number 6, Pages 467-476

2004

• Gene Therapy Progress and Prospects: Bringing gene therapy into medical practice: the evolution of international ethics and the regulatory environment
  J Spink and D Geddes
  Gene Therapy 2004 Nov, Vol. 11, No. 22; Pg. 1611–1616
• Insertional oncogenesis in gene therapy: how much of a risk?
  M Sadelain
  Gene Therapy 2004 April; 11, 569-573
• The future of gene therapy
  Marina Cavazzana-Calvo, Adrian Thrasher & Fulvio Mavilio
  Nature 26 February 2004, 427, 779 - 781

2003

• Perspectives on gene therapy for lysosomal storage diseases that affect hematopoiesis.
  Grabowski GA.
  Current Hematology Reports 2003 Jul; 2(4): 356-62.
• Gene Therapy for the Hemoglobin
  Derek A Persons MD PhD and Arthur W Nienhuis MD
  Current Hematology Reports 2003, 2:348-355 (published 1 July 2003)

2002

• Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus.
  Manfredi G, Fu J, Ojaimi J, Sadlock JE, Kwong JQ, Guy J, Schon EA.
  Nature Genetics 2002 Apr; 30(4): 394-9
• Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy.
  Dell'Eva R, Pfeffer U, Indraccolo S, Albini A, Noonan D.
  Endothelium 2002; 9(1): 3-10.

2001

• SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.
  Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG.
  Nature Genetics 2001 May;28(1):4-5.

2000

• Tailoring vectors through DNA shuffling.
  Curiel DT.
  Nature Genetics 2000 Aug; 25(4): 366-7.
• Learning from lentiviruses.
  Emerman M
  Nature Genetics 2000 Jan; 24(1): 8-9.

---

Reproductive genomics

2003

• Bovine embryo technologies.
  Galli C, Duchi R, Crotti G, Turini P, Ponderato N, Colleoni S, Lagutina I, Lazzari G.
  Theriogenology 2003 Jan 15; 59(2): 599-616.

2002

• Emerging role of genomics in endometriosis research.
  Taylor RN, Lundeen SG, Giudice LC.
  Fertility and sterility 2002 Oct; 78(4): 694-8.
• Genetic approaches to unraveling reproductive disorders: examples of bedside to bench research in the genomic era.
  Seminara SB, Crowley WF, Jr.
  Endocrine reviews 2002 Jun; 23(3): 382-92.
• Reproductive options for individuals at risk for transmission of a genetic disorder.
  Jones SL, Fallon LA.
  Journal of obstetric, gynecologic, and neonatal nursing 2002 Mar-Apr; 31(2): 193-9.
• Functional genomics in reproductive medicine.
  Barratt CL, Hughes DC, Afnan M, Brewis IA.
  Human Fertility (Camb) 2002 Feb; 5(1): 3-5.

2001

• Genomic and proteomic techniques applied to reproductive biology.
  Rockett JC.
  Genome Biology 2001 Aug; 2(9):REPORTS4020.

2000

• The ethical challenges of in utero gene therapy
  Caplan AL, Wilson JM
  Nature Genetics 2000 Feb; 24(2): 107.

---

Genetic databanks

2003

• Kinase pathway database: an integrated protein-kinase and NLP-based protein-interaction resource.
  Koike A, Kobayashi Y, Takagi T
  Genome Research 2003 Jun; 13(6A): 1231-43
• Genomic medicine. African-American population biobank proposed.
  Kaiser J
  Science 2003 Jun 6; 300 (5625):1485.
• UK Biobank: a project in search of a protocol?
  Barbour V.
  Lancet 2003 May 17; 361(9370): 1734-8
• Commercial biobanks and genetic research: ethical and legal issues.
  Anderlik M
  American journal of pharmacogenomics 2003; 3(3):203

2000

• Ethical guideposts for allelic variation databases.
  Knoppers BM, Laberge CM.
  Human Mutation 2000; 15(1): 30-5.

---

Pharmacogenomics

• More information on Pharmacogenomics

2005

• The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies
  A Woelderink, D Ibarreta, MM Hopkins and E Rodriguez-Cerezo
  The Pharmacogenomics Journal (2006) 6, 3–7; 29 November 2005
• Pharmacogenetics and the concept of individualized medicine
  BS Shastry
  The Pharmacogenomics Journal (2006) 6, 16–21 22 November 2005 @2006 Nature Publishing Group
• Cancer Pharmacogenomics May Require Both Qualitative and Quantitative Approaches
  Qing Cheng and William E. Evans
  Cell Cycle 4:11, 1506-1509, November 2005; ©2005 Landes Bioscience
• Racializing Drug Design: Implications of Pharmacogenomics for Health Disparities
  Sandra Soo-Jin Lee
  Am J Public Health. 2005 Dec; 95(12):2133-8.
• Pharmacogenetics and geographical ancestry: implications for drug development and global health
  pdf, 185kb
  Abdallah S. Daar and Peter A. Singer
  Nature Reviews Genetics March 2005; Vol 6; Pg 241-246
  -Reprinted by permission from Nature Reviews Genetics Vol. 6 pp. 241-246 Copyright © 2005 Macmillan Magazines Ltd.
• Stored tissue samples: through the confidentiality maze
  Y Joly, BM Knoppers and MT Nguyen,
  The Pharmacogenomics Journal (2005) 5, 2–5.

2004

• Pharmacogenetics—expectations and reality
  Geoff Tucker
  British Medical Journal3 July 2004; Vol 329;4-6
• Pharmacogenetics in the treatment of breast cancer
  V Stearns, N E Davidson & D A Flockhart
  The Pharmacogenomics Journal 2004, Vol 4, No 3, 143-153.
• A functional genomic study on NCI's anticancer drug screen
  K-C Li & S Yuan
  The Pharmacogenomics Journal 2004;Vol 4; Issue 2; 127-135

2003

• Inheritance and Drug Response
  Richard Weinshilboum
  The New England Journal of Medicine 6 Feb 2003, Vol 348: 529-537
• Pharmacogenetics and existing therapies
  Personal Perspective
  WHO Drug Information 2003, Vol 7, No.2
• Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy.
  Lockhart AC, Tirona RG, Kim RB.
  Molecular Cancer Therapeutics 2003 Jul; 2(7): 685-98
• Recruiting Genes, Proteins for a Revolution in Diagnostics
  Robert F. Service
  Science, 2003 Apr 11, Vol 300, Issue 5617, 236-239.
• Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.
  Schmitz G, Drobnik W.
  Clinical Chemistry and Laboratory Medicine 2003 Apr; 41(4): 581-9
• Pharmacogenomics of drugs affecting the cardiovascular system.
  Siest G, Ferrari L, Accaoui MJ, Batt AM, Visvikis S.
  Clinical Chemistry and Laboratory Medicine 2003 Apr; 41(4): 590-9
• Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.
  Guillemette C.
  The Pharmacogenetics Journal 2003; 3(3): 136-158
• Inheritance and Drug Response
  Weinshilboum R. New England Journal of
  Medicine 2003 Feb 6; 348(6): 529-37
• Pharmacogenomics--drug disposition, drug targets, and side effects.
  Evans WE, McLeod HL.
  New England Journal of Medicine 2003 Feb 6; 348(6): 538-49

2002

• Pharmacogenomics: the future of drug therapy.
  Tsai YJ, Hoyme HE.
  Clinical Genetics 2002; 62 (4): 257-264.
• Ethical, social and legal implications of pharmacogenomics: a critical review.
  Moldrup C.
  Community Genetics 2002 Jun; 4(4): 204-14.

2000

• A gene expression database for the molecular pharmacology of cancer.
  Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG. Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN.
  Nature Genetics 2000 Mar; 24(3): 236-44